SOVREMENNAYa PERORAL'NAYa TERAPIYa EREKTIL'NOY DISFUNKTsII
- Authors: Akhvlediani N.D1
-
Affiliations:
- Issue: No 3 (2013)
- Pages: 84-87
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/280301
- ID: 280301
Cite item
Open Access
Access granted
Abstract
This review article considers the issues of modern treatment of erectile dysfunction using oral drugs. The comparative data on the effectiveness of various phosphodiesterase type 5 inhibitors are presented. Information about the new drug of this group - Cialis (tadalafil) - 5 mg for daily use, is provided. It is emphasized that the innovative concept of therapy of erectile dysfunction with the use of specially designed phosphodiesterase type 5 inhibitor of for everyday application opens up new potentials for the correction of erectile dysfunction.
Full Text
References
- NIH Consensus Conference. JAMA 1993;270(1):83-90.
- Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994;151:54-61.
- Rosen RC, Fisher WA, Eardley I, et al. Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20(5): 607-17.
- Глыбочко П.В., Аляев Ю.Г., Ахвледиани Н.Д. и др. Практическая урология. Руководство для врачей. М.: Медфорум. 2012. С. 265-95.
- Martin-Morales A, Haro JM, Beardsworth A, Bertsch J, Kontodimas S; EDOS Group. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). Eur Urol 2007;51(2):541-50.
- Chun J, Carson CC 3rd. Physician-patient dialogue and clinical evaluation of erectil dysfunction. Urol Clin North Am 2001;28:249-58.
- Perelman MA. Sex coaching for physicians: Combination treatment for patient and partner. Int J Impot Res 2003;15(5 suppl): S67-74.
- Rosen RC, Fisher WA, Eardley I, et al; Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20(5):607-17.
- Holden CA, Jolley DJ, McLachlan RI, et al. Men in Australia Telephone Survey (MATeS): predictors of men's help-seeking behaviour for reproductive health disorders. Med J Aust 2006;185(8):418-22.
- Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006;60(8):967-75.
- Kim TE, Kim BH, Kim JR, et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5-inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol 2009;68(1):43-6.
- Lee J, Pommerville P, Brock G, et al. Physicianrated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study. BJU Int 2006;98(3):623-29.
- Fisher WA, Rosen RC, Eardley I, Sand M, Goldstein I. Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med 2005;2(5):675-84.
- Dunn ME, Althof SE, Perelman MA. Phosphodiesterase type 5 inhibitors extended duration of response as a variable in the treatment of erectile dysfunction. Int J Impot Res 2007;19(2):119-23.
- Washington SL 3rd, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther 2010;4:159-71.
- Инструкция для специалистов по медицинскому применению препарата Сиалис® 20 мг (тадалафил), П № 014761/01-050309.
- Инструкция для специалистов по медицинскому применению препарата Сиалис® 5 мг (тадалафил), ЛП-000133 от 11.01.2011.
- Seftel A, Goldfischer E, Kim ED, et al. Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial. J Urol 2011;185(1):243-48.
- Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006;50(2):351-59.
- Carson CC, Rajfer J, Eardley I, et. The efficacy and safety of tadalafil: an update. BJU Int 2004;93(9):1276-81.
- Porst H, Rajfer J, Casab A, et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008;5(9):2160-69.
- Rubio-Aurioles E, Porst H, Kim ED, et al. A Randomized Open-Label Trial with a Crossover Comparison of Sexual Self-Confidence and Other Treatment Outcomes Following Tadalafil Once a Day Vs. Tadalafil or Sildenafil On-Demand in Men with Erectile Dysfunction. J Sex Med 2012;9(5):1418-29.
Supplementary files
